STC1 is a Novel Biomarker Associated with Immune Characteristics and Prognosis of Bladder Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249.
   PubMed Web of Science ®Google Scholar
• Tan WS, Kelly JD. Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nat Rev Urol. 2018;15(11):667–685. doi:10.1038/s41585-018-0092-z
   PubMed Web of Science ®Google Scholar
• Kufukihara R, Kikuchi E, Ogihara K, et al. Role of Previous Malignancy History in Clinical Outcomes in Patients with Initially Diagnosed Non-Muscle Invasive Bladder Cancer. Ann Surg Oncol. 2021;28(9):5349–5359. doi:10.1245/s10434-021-09750-0
   Google Scholar
• Witjes JA, Bruins HM, Cathomas R, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82–104. doi:10.1016/j.eururo.2020.03.055
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Petrylak DP. New therapeutic challenges in advanced bladder cancer. Semin Oncol. 2012;39(5):598–607. doi:10.1053/j.seminoncol.2012.08.007
   PubMed Web of Science ®Google Scholar
• Stenehjem DD, Tran D, Nkrumah MA, Gupta S. PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. Onco Targets Ther. 2018;11:5973–5989. doi:10.2147/OTT.S135157
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026. doi:10.1056/NEJMoa1613683
   PubMed Web of Science ®Google Scholar
• Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312–322. doi:10.1016/S1470-2045(17)30065-7
   PubMed Web of Science ®Google Scholar
• Fradet Y, Bellmunt J, Vaughn DJ, et al. Randomized Phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019;30(6):970–976. doi:10.1093/annonc/mdz127
   PubMed Web of Science ®Google Scholar
• Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76. doi:10.1016/S0140-6736(16)32455-2
   PubMed Web of Science ®Google Scholar
• Chang AC, Janosi J, Hulsbeek M, et al. A novel human cDNA highly homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol. 1995;112(2):241–247. doi:10.1016/0303-7207(95)03601-3
   PubMed Web of Science ®Google Scholar
• Yoshiko Y, Aubin JE. Stanniocalcin 1 as a pleiotropic factor in mammals. Peptides. 2004;25(10):1663–1669. doi:10.1016/j.peptides.2004.04.015
   PubMed Web of Science ®Google Scholar
• Zhao F, Yang G, Feng M, et al. Expression, function and clinical application of stanniocalcin-1 in cancer. J Cell Mol Med. 2020;24(14):7686–7696. doi:10.1111/jcmm.15348
   PubMed Web of Science ®Google Scholar
• Li Y, He ZC, Zhang XN, et al. Stanniocalcin-1 augments stem-like traits of glioblastoma cells through binding and activating NOTCH1. Cancer Lett. 2018;416:66–74. doi:10.1016/j.canlet.2017.11.033
   PubMed Web of Science ®Google Scholar
• Jeon M, Han J, Nam SJ, Lee JE, Kim S. STC-1 expression is upregulated through an Akt/NF-κB-dependent pathway in triple-negative breast cancer cells. Oncol Rep. 2016;36(3):1717–1722. doi:10.3892/or.2016.4972
   PubMed Web of Science ®Google Scholar
• Chan KK, Leung CO, Wong CC, et al. Secretory Stanniocalcin 1 promotes metastasis of hepatocellular carcinoma through activation of JNK signaling pathway. Cancer Lett. 2017;403:330–338. doi:10.1016/j.canlet.2017.06.034
   PubMed Web of Science ®Google Scholar
• Cui X, Shen D, Kong C, et al. NF-κB suppresses apoptosis and promotes bladder cancer cell proliferation by upregulating survivin expression in vitro and in vivo. Sci Rep. 2017;7:40723. doi:10.1038/srep40723
   PubMed Web of Science ®Google Scholar
• Shen KH, Li CF, Chien LH, et al. Role of galectin-1 in urinary bladder urothelial carcinoma cell invasion through the JNK pathway. Cancer Sci. 2016;107(10):1390–1398. doi:10.1111/cas.13016
   PubMed Web of Science ®Google Scholar
• Brantley KD, Kjaersgaard A, Cronin-Fenton D, et al. Stanniocalcin expression as a predictor of late breast cancer recurrence. Cancer Epidemiol Biomarkers Prev. 2018;27(6):653–659. doi:10.1158/1055-9965.EPI-17-0905
   PubMed Web of Science ®Google Scholar
• Shirakawa M, Fujiwara Y, Sugita Y, et al. Assessment of stanniocalcin-1 as a prognostic marker in human esophageal squamous cell carcinoma. Oncol Rep. 2012;27(4):940–946. doi:10.3892/or.2011.1607
   PubMed Web of Science ®Google Scholar
• Lin H, Kryczek I, Li S, et al. Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance. Cancer Cell. 2021;39:480–493.
   PubMed Web of Science ®Google Scholar
• Schneider AK, Chevalier MF, Derre L. The multifaceted immune regulation of bladder cancer. Nat Rev Urol. 2019;16(10):613–630. doi:10.1038/s41585-019-0226-y
   PubMed Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–678. doi:10.1038/s41587-020-0546-8
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Dunn P, Thomas CG, et al. ImmPort, toward repurposing of open access immunological assay data for translational and clinical research. Sci Data. 2018;5:180015. doi:10.1038/sdata.2018.15
   PubMed Web of Science ®Google Scholar
• Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57. doi:10.1038/nprot.2008.211
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Cimadamore A, Blanca A, et al. Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers. 2021;13(1):131. doi:10.3390/cancers13010131
   PubMed Web of Science ®Google Scholar
• Fang Z, Tian Z, Luo K, Song H, Yi J. Clinical significance of stanniocalcin expression in tissue and serum of gastric cancer patients. Chin J Cancer Res. 2014;26(5):602–610.
   PubMed Web of Science ®Google Scholar
• Han J, Jeon M, Shin I, Kim S. Elevated STC1 augments the invasiveness of triple‑negative breast cancer cells through activation of the JNK/cJun signaling pathway. Oncol Rep. 2016;36(3):1764–1771. doi:10.3892/or.2016.4977
   PubMed Web of Science ®Google Scholar
• Bai Y, Xiao Y, Dai Y, et al. Stanniocalcin 1 promotes cell proliferation via cyclin E1/cyclin‑dependent kinase 2 in human prostate carcinoma. Oncol Rep. 2017;37(4):2465–2471. doi:10.3892/or.2017.5501
   PubMed Web of Science ®Google Scholar
• Ma X, Gu L, Li H, et al. Hypoxia-induced overexpression of stanniocalcin-1 is associated with the metastasis of early stage clear cell renal cell carcinoma. J Transl Med. 2015;13:56. doi:10.1186/s12967-015-0421-4
   PubMed Web of Science ®Google Scholar
• Tsukamoto H, Fujieda K, Miyashita A, et al. Combined blockade of IL6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment. Cancer Res. 2018;78(17):5011–5022. doi:10.1158/0008-5472.CAN-18-0118
   PubMed Web of Science ®Google Scholar
• Zeng Y, Li B, Liang Y, et al. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment. FASEB J. 2019;33(5):6596–6608. doi:10.1096/fj.201802067RR
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–322. doi:10.1038/nature12965
   PubMed Web of Science ®Google Scholar
• Schcolnik-Cabrera A, Oldak B, Juarez M, Cruz-Rivera M, Flisser A, Mendlovic F. Calreticulin in phagocytosis and cancer: opposite roles in immune response outcomes. Apoptosis. 2019;24(3–4):245–255. doi:10.1007/s10495-019-01532-0
   PubMed Web of Science ®Google Scholar
• Lei X, Lei Y, Li JK, et al. Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy. Cancer Lett. 2020;470:126–133. doi:10.1016/j.canlet.2019.11.009
   PubMed Web of Science ®Google Scholar
• Krpina K, Babarovic E, Jonjic N. Correlation of tumor-infiltrating lymphocytes with bladder cancer recurrence in patients with solitary low-grade urothelial carcinoma. Virchows Arch. 2015;467(4):443–448. doi:10.1007/s00428-015-1808-6
   PubMed Web of Science ®Google Scholar
• Patschan O, Sjodahl G, Chebil G, et al. A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma. Eur Urol. 2015;68(5):824–832. doi:10.1016/j.eururo.2015.02.021
   PubMed Web of Science ®Google Scholar
• Rouanne M, Betari R, Radulescu C, et al. Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer. Eur J Cancer. 2019;108:111–119. doi:10.1016/j.ejca.2018.12.010
   PubMed Web of Science ®Google Scholar
• Tille JC, Vieira AF, Saint-Martin C, et al. Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. Mod Pathol. 2020;33(11):2198–2207. doi:10.1038/s41379-020-0561-9
   PubMed Web of Science ®Google Scholar
• Petitprez F, Fossati N, Vano Y, et al. PD-L1 expression and CD8(+) T-cell infiltrate are associated with clinical progression in patients with node-positive prostate cancer. Eur Urol Focus. 2019;5(2):192–196. doi:10.1016/j.euf.2017.05.013
   PubMedGoogle Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–1570. doi:10.1126/science.1203486
   PubMed Web of Science ®Google Scholar